Ahmed Rowan, Kareem Roaa, Venkatesan Nanditha, Botleroo Rinky A, Ogeyingbo Opemipo D, Bhandari Renu, Gyawali Mallika, Elshaikh Abeer O
Internal Medicine/Family Medicine, California Institute of Behavioral Neurosciences & Psychology, Fairfield, USA.
Internal Medicine, All India Institute of Medical Sciences, Raipur, IND.
Cureus. 2021 Aug 16;13(8):e17237. doi: 10.7759/cureus.17237. eCollection 2021 Aug.
Hepatitis C virus (HCV) infection is a disease that affects millions of people worldwide and has an enormous global public health impact. Chronic HCV is a long-term infection that goes unnoticed until the virus destroys the liver enough to induce liver disease symptoms. The inadequate and poorly tolerated treatment contributes to the burden of chronic HCV. Treatments have improved over time - direct-acting antivirals (DAAs) that targeted different hepatitis C virus genomic sites have shown to be more effective and well-tolerated. Patients recover to a greater extent following a treatment regimen based on DAAs. We conducted this literature review to investigate the effectiveness of these medications in treating chronic HCV infection. Relevant articles were identified by searching PubMed and Google scholar databases. Our primary goal was to analyze the efficacy and safety of the DAA, sofosbuvir plus velpatasvir, with or without ribavirin, in cirrhotic or non-cirrhotic, naïve or previously treated, chronic HCV patients. We found that treating patients with sofosbuvir-velpatasvir for 12 weeks was highly effective with fewer adverse events, including those with compensated cirrhosis. The outcomes aided in improving HCV treatment, lowering the disease's burden and fatality rate.
丙型肝炎病毒（HCV）感染是一种影响全球数百万人的疾病，对全球公共卫生产生了巨大影响。慢性丙型肝炎病毒感染是一种长期感染，在病毒对肝脏造成足够破坏从而引发肝病症状之前往往不被察觉。治疗方法不足且耐受性差加重了慢性丙型肝炎的负担。随着时间的推移，治疗方法有所改进——针对不同丙型肝炎病毒基因组位点的直接抗病毒药物（DAAs）已被证明更有效且耐受性良好。采用基于DAAs的治疗方案后，患者恢复程度更高。我们进行了这项文献综述，以研究这些药物治疗慢性丙型肝炎病毒感染的有效性。通过检索PubMed和谷歌学术数据库确定了相关文章。我们的主要目标是分析DAA药物索磷布韦加维帕他韦（无论是否联用利巴韦林）在肝硬化或非肝硬化、初治或经治的慢性丙型肝炎患者中的疗效和安全性。我们发现，用索磷布韦-维帕他韦治疗患者12周非常有效，不良事件较少，包括代偿期肝硬化患者。这些结果有助于改善丙型肝炎的治疗，降低疾病负担和死亡率。
